FDA Inspection 1218963 — Vivus, Inc.
The FDA completed an inspection of Vivus, Inc. on September 8, 2023 in Campbell, CA. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- September 8, 2023
- Fiscal Year
- 2023
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Campbell, CA (United States)
Additional Details
Risk Evaluation and Mitigation Strategies (REMS)